Risk stratification of newly diagnosed multiple myeloma patients

Simple item page
dc.contributor.authorAra Islam, I.en_US
dc.contributor.authorSamarat, M. H.en_US
dc.contributor.authorMahzabin, N.en_US
dc.contributor.authorJahan, N.en_US
dc.contributor.authorAkhlak-Ul-Islam, M.en_US
dc.contributor.authorShah, M. S.en_US
dc.contributor.authorPoddar, S. C.en_US
dc.contributor.authorReza Kabir, M. M.en_US
dc.contributor.authorNasrin, P.en_US
dc.contributor.authorRahman, M. A.en_US
dc.contributor.authorAkhter, N.en_US
dc.contributor.authorAfroz Chowdhury, N.en_US
dc.contributor.authorKhan, M. R.en_US
dc.date.accessioned2024-09-24T09:22:36Z
dc.date.available2024-09-24T09:22:36Z
dc.date.issued2024-05
dc.description.abstractBackground: Multiple Myeloma is a neoplastic proliferation of plasma cells, associated with an M (monoclonal) protein in serum and/or urine and evidence of organ damage. Despite advances in treatment, the disease remains heterogeneous, necessitating a comprehensive understanding of its risk stratification. Risk-adapted initial therapy, maintenance therapy, refractory disease management and prognosis varies according to risk group. The aim of our study is to categorize the newly diagnosed MM patients according to their risk groups. Methods: This cross-sectional observational study was conducted at the Department of Haematology of Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, from August 2019 to July 2020. A total of 31 newly diagnosed MM patients were enrolled based on specific inclusion and exclusion criteria. Risk stratification was performed using ISS, R-ISS, mSMART criteria and Avets risk group categorization. Result: The majority of the patients were male (64.52%) and aged between 55-64 years (45.16%). Clinical features predominantly included low back pain (74.19%) and general weakness (38.71%). Cytogenetic abnormalities were noted in 38.7% of the patients, with del (13q) being the most common (32.30%). Most patients were in ISS Stage III (70.97%) and R-ISS Stage II (48.39%). According to mSMART criteria, 80.65% were at standard risk while Avet's risk stratification identifies 58.06% were at intermediate risk. Conclusion: The study reveals a high prevalence of patients in advanced ISS stages and intermediate to high-risk categories, emphasizing the need for early and personalized intervention strategies.en_US
dc.identifier.affiliationsDepartment of Haematology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Orthopaedic, National Institute of Traumatology and Orthopaedic Rehabilitation, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pediatric Haematology and Oncology, Dhaka Medical College Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Haematology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladeshen_US
dc.identifier.affiliationsMongla Upazilla Health Complex, Khulna, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pediatric Haematology and Oncology, Dhaka Medical College Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Haematology, Sir Salimullah Medical College and Mitford Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Medicine, Sheikh Hasina Medical College Hospital, Tangail, Bangladeshen_US
dc.identifier.affiliationsDepartment of Haematology, Dhaka Medical College Hospital, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDirectorate General of Health Services, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Haematology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladeshen_US
dc.identifier.citationAra Islam I., Samarat M. H., Mahzabin N., Jahan N., Akhlak-Ul-Islam M., Shah M. S., Poddar S. C., Reza Kabir M. M., Nasrin P., Rahman M. A., Akhter N., Afroz Chowdhury N., Khan M. R.. Risk stratification of newly diagnosed multiple myeloma patients. International Journal of Research in Medical Sciences. 2024 May; 12(5): 1402-1407en_US
dc.identifier.issn2320-6071
dc.identifier.issn2320-6012
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/234092
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber5en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.18203/2320-6012.ijrms20241219en_US
dc.subjectMyelomaen_US
dc.subjectRisk stratificationen_US
dc.subjectCytogeneticen_US
dc.subjectISSen_US
dc.subjectR-ISSen_US
dc.subjectmSMARTen_US
dc.titleRisk stratification of newly diagnosed multiple myeloma patientsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijrms2024v12n5p1402.pdf
Size:
211.51 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Research in Medical Sciences